Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | GUSB | P08236 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | DHODH | Q02127 | 5/20 | 0.48 |
| ▸ | MAOA | P21397 | 3/20 | 0.47 |
| ▸ | MAOB | P27338 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25613698 | 0.89 | MEN1 (0.62) | EGFRMEN1MAPTKMT2ASMN1; SMN2 | |
| SCHEMBL25614339 | 0.89 | DHODH (0.50) | EGFRMEN1MAPTKMT2ASMN1; SMN2 | |
| SCHEMBL25613755 | 0.87 | DHODH (0.56) | MEN1MAPTKMT2ASMN1; SMN2GUSB | |
| SCHEMBL25613688 | 0.87 | EGFR (0.52) | EGFRMEN1MAPTKMT2ASMN1; SMN2 | |
| SCHEMBL25614001 | 0.85 | DHODH (0.48) | EGFRMEN1MAPTKMT2ASMN1; SMN2 | |
| SCHEMBL25614555 | 0.84 | DHODH (0.48) | EGFRMEN1MAPTKMT2ASMN1; SMN2 | |
| SCHEMBL25613810 | 0.79 | DHODH (0.64) | EGFRMEN1MAPTKMT2ASMN1; SMN2 | |
| SCHEMBL25613950 | 0.79 | DHODH (0.61) | EGFRMEN1MAPTKMT2ASMN1; SMN2 | |
| SCHEMBL25613990 | 0.78 | DHODH (0.69) | EGFRMEN1MAPTKMT2ASMN1; SMN2 | |
| SCHEMBL25614091 | 0.78 | EGFR (0.59) | EGFRMEN1MAPTKMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230190713-A1 | ANTI-RNA VIRUS DRUG AND APPLICATION THEREOF | EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) | 2023-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230190713-A1 | ANTI-RNA VIRUS DRUG AND APPLICATION THEREOF | SARS1, EIF2AK2, NSUN3 | EGFR 3094/4885MEN1 4853/4885MAPT 1783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.